PT1441724E - Métodos para aumentar os níveis endógenos de testosterona - Google Patents

Métodos para aumentar os níveis endógenos de testosterona Download PDF

Info

Publication number
PT1441724E
PT1441724E PT02766382T PT02766382T PT1441724E PT 1441724 E PT1441724 E PT 1441724E PT 02766382 T PT02766382 T PT 02766382T PT 02766382 T PT02766382 T PT 02766382T PT 1441724 E PT1441724 E PT 1441724E
Authority
PT
Portugal
Prior art keywords
pyrazol
tert
pyridin
butylphenyl
tyrosinamide
Prior art date
Application number
PT02766382T
Other languages
English (en)
Portuguese (pt)
Inventor
Sean Mckenna
William H Brondyk
Stephen J Arkinstall
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Publication of PT1441724E publication Critical patent/PT1441724E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT02766382T 2001-09-27 2002-09-27 Métodos para aumentar os níveis endógenos de testosterona PT1441724E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32547001P 2001-09-27 2001-09-27

Publications (1)

Publication Number Publication Date
PT1441724E true PT1441724E (pt) 2007-10-15

Family

ID=23268011

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02766382T PT1441724E (pt) 2001-09-27 2002-09-27 Métodos para aumentar os níveis endógenos de testosterona

Country Status (12)

Country Link
US (1) US20040198799A1 (enExample)
EP (1) EP1441724B8 (enExample)
JP (1) JP2005504093A (enExample)
AT (1) ATE372114T1 (enExample)
AU (1) AU2002330120B2 (enExample)
CA (1) CA2458661A1 (enExample)
DE (1) DE60222286T2 (enExample)
DK (1) DK1441724T3 (enExample)
ES (1) ES2289143T3 (enExample)
IL (1) IL161047A0 (enExample)
PT (1) PT1441724E (enExample)
WO (1) WO2003026649A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6914069B2 (en) * 2000-05-19 2005-07-05 Applied Research Systems Ars Holding N.V. Pharmaceutically active compounds and methods of use
WO2004016592A1 (en) * 2002-08-14 2004-02-26 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
US8241664B2 (en) 2005-04-15 2012-08-14 Clarus Therapeutics, Inc Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
MX2008000141A (es) * 2005-06-27 2008-04-07 Exelixis Inc Moduladores de lxr basados en imidazol.
JP5110478B2 (ja) 2006-06-23 2012-12-26 株式会社J−オイルミルズ テストステロン増加剤
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
MY161598A (en) * 2009-01-30 2017-04-28 Glaxosmithkline Llc Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
WO2011161615A1 (en) 2010-06-24 2011-12-29 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
WO2011161645A1 (en) 2010-06-25 2011-12-29 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
JP5860459B2 (ja) 2010-06-30 2016-02-16 アイアンウッド ファーマシューティカルズ インコーポレイテッド sGC刺激薬
ES2572803T3 (es) 2010-11-09 2016-06-02 Ironwood Pharmaceuticals, Inc. Estimuladores de GCs
US9139564B2 (en) 2011-12-27 2015-09-22 Ironwood Pharmaceuticals, Inc. 2-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665898B1 (fr) * 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
DE4039733A1 (de) * 1990-12-13 1992-06-17 Basf Ag Substituierte 5-aminopyrazole
BR9307664A (pt) * 1992-12-17 1999-06-29 Pfizer Pirazóis substituídos como antagonistas
KR960705808A (ko) * 1993-11-09 1996-11-08 조셉 에프. 디프리마 성장 호르몬의 방출을 촉진시키는 피페리딘, 피롤리딘 및 헥사하이드로-1H-아제핀(Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone)
US5869688A (en) * 1994-07-20 1999-02-09 Monsanto Company Preparation of substituted 3-aryl-5-haloalkyl-pyrazoles having herbicidal activity
CA2288787A1 (en) * 1997-05-22 1998-11-26 G.D. Searle And Co. Pyrazole derivatives as p38 kinase inhibitors
CA2308428A1 (en) * 1997-11-03 1999-05-14 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
ATE301129T1 (de) * 1999-05-04 2005-08-15 Strakan Int Ltd Androgen glykoside und die androgenische aktivität davon
US6914069B2 (en) * 2000-05-19 2005-07-05 Applied Research Systems Ars Holding N.V. Pharmaceutically active compounds and methods of use
CZ2003468A3 (cs) * 2000-08-31 2004-05-12 Pfizeráproductsáinc Deriváty pyrazolu a jejich použití jako inhibitorů proteinkinázy

Also Published As

Publication number Publication date
DE60222286D1 (de) 2007-10-18
EP1441724B1 (en) 2007-09-05
DE60222286T2 (de) 2008-06-19
EP1441724B8 (en) 2007-10-17
DK1441724T3 (da) 2007-12-03
JP2005504093A (ja) 2005-02-10
IL161047A0 (en) 2004-08-31
ES2289143T3 (es) 2008-02-01
US20040198799A1 (en) 2004-10-07
WO2003026649A1 (en) 2003-04-03
EP1441724A1 (en) 2004-08-04
CA2458661A1 (en) 2003-04-03
AU2002330120B2 (en) 2007-10-11
ATE372114T1 (de) 2007-09-15

Similar Documents

Publication Publication Date Title
US10988475B2 (en) Agonists of the apelin receptor and methods of use thereof
CN102159573B (zh) 作为nadph氧化酶抑制剂的吡唑并吡啶衍生物
KR102367876B1 (ko) 오토탁신 억제제 화합물
ES2401679T3 (es) Derivados de 6-1H-imidazo-quinazolina y de quinolinas, nuevos inhibidores de MAO y ligandos del receptor de imidazolina
CN102137863B (zh) 作为nadph氧化酶抑制剂的吡唑并吡啶衍生物
JPH11506471A (ja) ゴナドトロピン放出ホルモン拮抗剤
JP2009531439A (ja) 前立腺癌およびアンドロゲン受容体関連病態の治療のためのアンドロゲン受容体の調節剤
BR112018016484B1 (pt) Composto, composição farmacêutica e uso de um composto
KR19990072124A (ko) 고나도트로핀 방출 호르몬의 길항제
BR112012007828B1 (pt) compostos inibidores da xantina oxidase, processo para preparar os compostos, e, composição farmacêutica para a inibição da xantina oxidase
EA013207B1 (ru) Ингибиторы вирусной полимеразы
AU2006281594A1 (en) Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
PT1441724E (pt) Métodos para aumentar os níveis endógenos de testosterona
ES2243504T3 (es) Uso de derivados de pirazol para tratar la infertilidad.
US20030139431A1 (en) Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors
EP1911755B1 (en) Benzoimidazole compound capable of inhibiting prostaglandin d synthetase
JP2002520409A (ja) ゴナドトロピン放出ホルモン拮抗薬
AU2001264694A1 (en) Use of pyrazole derivatives for treating infertility
AU2002330120A1 (en) Methods of increasing endogenous testosterone levels
KR20100046107A (ko) 벤즈이미다졸 유도체
CN114302881A (zh) 适用于治疗和预防肌肉萎缩和其他状况的化合物
CN116438181A (zh) 磺酰胺基取代的杂芳基嘧啶二酮类化合物及其用途
HK1174623A (en) Pyrazolo piperidine derivatives as nadph oxidase inhibitors